You are here

Approvals, Launches, and New Indications

Intramuscular injection of incobotulinumtoxinA improves muscle tone
Generic product developed in response to agency warning
AstraZenecas’s new treatment has been approved in combination with a xanthine oxidase inhibitor
The drug will be made available in the U.S. in early 2016
First insulin treatment approved through abbreviated approval pathway
Technology involves millions of tiny particles
Alectinib treats ALK-positive NSCLC
Medication treats overdose with fluorouracil or capecitabine
Marketing expected to start in early 2016
First product to receive FDA approval for this indication in children
Vonvendi indicated for on-demand treatment in adults
Product expected to be available in early 2016
Sebelipase provides missing protein in lysosomal acid lipase deficiency
Expandable sponges fill wound cavity, stop bleeding
Bristol-Myers treatment stimulates the immune response
The drug is now a first-line single agent for advanced BRAF wild-type melanoma
The drug blocks certain enzymes, hindering cancer-cell growth
Adapt Pharma's drug is the first-ever nasal spray version of naloxone

Pages